bortezomib + G-CSF

Bortezomib is a small molecule proteasome inhibitor primarily used in the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting the 26S proteasome, leading to disruption of protein degradation and induction of apoptosis in cancer cells. Granulocyte colony-stimulating factor (G-CSF) is a cytokine that stimulates the bone marrow to produce neutrophils and other granulocytes, commonly used to promote white blood cell recovery after chemotherapy or for mobilization of hematopoietic stem cells. The combination of bortezomib with G-CSF has been investigated as a regimen for enhanced mobilization of hematopoietic stem and progenitor cells (HSPCs) prior to autologous stem cell transplantation, particularly in patients with multiple myeloma. Bortezomib enhances the effect of G-CSF by downregulating CXCL12 chemokine expression in bone marrow, increasing vascular permeability, and facilitating dissociation and mobilization of HSPCs into peripheral blood[1][2][4]. This combination may also restore effective granulocytic differentiation in certain congenital neutropenia cases unresponsive to high-dose G-CSF alone[6].

Brand names

VelcadeNeupogen

Other names

granulocyte colony-stimulating factorgranulocyte-colony stimulating factorfilgrastim (for G-CSF)pegfilgrastim (for G-CSF)